Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1RLY2
|
|||
| Drug Name |
CERC 006
|
|||
| Synonyms |
OSI-027; 936890-98-1; OSI027; OSI 027; 25MKH1SZ0M; AEVI-006; CERC-006; ASP-7486; 936890-98-1 (free acid); 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; UNII-25MKH1SZ0M; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; CERC006; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; MLS006011006; SCHEMBL976795; SCHEMBL976796; CERC 006; CHEMBL2132692; CHEMBL3120215; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; CHEBI:91363; ASP4786; ASP7486; EX-A143; JROFGZPOBKIAEW-HAQNSBGRSA-N; BDBM185151; DTXSID901025951; HMS3656H05; HMS3748I11; ASP 7486; BCP02613; NSC800810; s2624; AKOS030238938; AKOS037643584; AM81260; BCP9001034; CCG-268721; CS-0257; DB12387; NSC-800810; SB19259; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; (+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; AC-31517; AS-17003; HY-10423; LS-14875; SMR004702804; SW220246-1; A-1065; F17371; J-523839; BRD-K94294671-003-01-3; Q27163231; Q27253978; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Lymphatic malformation [ICD-11: LA90.1] | Phase 1 | [1] | |
| Company |
Avalo Therapeutics Wayne, PA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22N6O3
|
|||
| Canonical SMILES |
COC1=CC=CC2=C1NC(=C2)C3=C4C(=NC=NN4C(=N3)C5CCC(CC5)C(=O)O)N
|
|||
| InChI |
InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)
|
|||
| InChIKey |
JROFGZPOBKIAEW-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04994002) A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.